Luxembourg, 13/05/2022

Environmental and Social Data Sheet

Overview

Project Name:	INVENTIVA - (EGFF)
Project Number:	20210353
Country:	France
Project Description:	Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs. The promoter's lead compound (Lanifibranor) is currently in phase III in NASH.

EIA required: no

Project included in Carbon Footprint Exercise[1]: no

(details for projects included are provided in section: "EIB Carbon Footprint Exercise")

Environmental and Social Assessment

Environmental Assessment

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs. The project will support the promoter's R&D activities to develop a pipeline of clinical and preclinical assets targeting high unmet medical needs in the areas of fibrosis, and oncology. The EIB investment will particularly co-finance the late stage clinical development of Lanifibranor clinical studies in advance stage NASH patients, including among other aspects regulatory and clinical batch production, as well as the development of the pre-clinical pipeline in oncology and fibrosis.

The project activities are not listed in any of the annexes of the EU Directive 2014/52/EU amending 2011/92/EU. Furthermore, the project will be carried out in existing facilities already authorised for similar activities and volumes. Therefore, the project is not subject to an Environmental Impact Assessment (EIA).

The promoter's R&D facilities and practices are in compliance with relevant national and EU regulations and the promoter maintains adequate internal procedures and management practices. The use of animal testing is minimised and in line with the EU Directive 2010/63/EU. In addition, the promoter has adequate policies and procedures in place to outsource and

[1] Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO2e/year absolute (gross) or 20,000 tonnes CO2e/year relative (net) – both increases and savings.

manage clinical trials in the different regions of the world in accordance with the EU 536/2014 regulation. The clinical trials, which are sponsored by the project, are performed under regulated and strictly controlled conditions, in existing specialised facilities, which are regularly inspected by competent authorities - EMA in Europe and/or national equivalent bodies in the rest of the world (e.g. FDA).

The project has been assessed for Paris alignment and is considered to be aligned both against low carbon and resilience goals.

Social Assessment, where applicable

If successful, the project is expected to lead to important social benefits stemming from its focus on the development of novel treatments for diseases with currently no cure and limited therapeutic options.

Through the R&D activities and investments, the promoter expects to increase its current level of highly skilled personnel, while contributing to European scientific innovation across several areas such as fibrosis and liver diseases as well as oncology treatment, hence fostering and nurturing the vital life science research community.

The promoter has a strong commitment towards the employment and promoting gender equity across all levels, with women representing 62% of the total employment and 56% in management positions (including the executive management and board members).

Conclusions and Recommendations

The project's activities are not listed in any of the annexes of the EU Directive 2014/52/EU amending 2011/92/EU, and the research activities will be executed in existing and authorised research facilities. Therefore, an Environmental Impact Assessment (EIA) is not required. The promoter has effective policies and operating procedures in place, which are in line with industry standards.